Prognostic and Predictive Impact of Soluble Epidermal Growth Factor Receptor (sEGFR) Protein in the Serum of Patients Treated with Chemotherapy for Metastatic Breast Cancer - Mueller, V; Witzel, I; Pantel, K; Krenkel, S; Luck, HJ; Neumann, R; Keller, T; Dittmer, J; Jaenicke, F; Thomssen, C (Anticancer research, 2006)
Keywords: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Breast Neoplasms - blood; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Cyclophosphamide - administration & dosage; Disease-Free Survival; Epirubicin - administration & dosage; Female; Gynecology. Andrology. Obstetrics; Humans; Mammary gland diseases; Medical sciences; Mucin-1 - blood; Neoplasm Metastasis; Paclitaxel - administration & dosage; Predictive Value of Tests; Receptor, Epidermal Growth Factor - blood; Receptor, ErbB-2 - blood; Solubility; Tumors; Human; Prognosis; Soluble factor; Breast cancer; Malignant tumor; Metastasis; Serum protein; Epidermal growth factor receptor; Mammary gland diseases; Chemotherapy; Growth factor receptor; Cancerology; Treatment; Advanced stage; Serum